GlassScriptPhysician profile
Mary E Barkalow
NPI 1700864485
$27,877.99
in general payments reported to CMS, 2019-2025
19 companies · $3,401 in 2025
The $3,401 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $1,374 · 2021: $6,239 · 2022: $8,572 · 2023: $3,565 · 2024: $3,244 · 2025: $3,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,938 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,937.96 |
| Education | $271.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,508.14 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,826.08 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $2,559.58 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $2,087.49 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,626.08 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $1,225.11 | 2019-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $1,159.79 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $1,123.44 | 2019-2022 | |
| Alkermes, INC. | $908.73 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $724.47 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $657.33 | 2024-2025 | Cobenfy |
| Allergan, INC. | $577.46 | 2019-2020 | |
| Axsome Therapeutics, INC. | $311.84 | 2024-2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $246.84 | 2019 | |
| Indivior INC. | $167.00 | 2025 | Sublocade |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $69.36 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $53.76 | 2019 | |
| Gilead Sciences, INC. | $26.33 | 2019 | |
| Shire North American Group INC | $19.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Barkalow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.